Where does Keygene N.V. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Keygene N.V. ranks #4,522 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Keygene N.V. hold?

Keygene N.V. holds 78 US utility patents granted between 2015 and 2025, spanning 18 technology areas.

What is Keygene N.V.'s Innovation Score?

Keygene N.V. has an Innovation Score of 43.8 out of 100 (top 27% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Keygene N.V.'s patent grant rate increasing or decreasing?

Keygene N.V.'s recent grant velocity is -52% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Keygene N.V.'s patents?

Keygene N.V.'s patents average 15.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Keygene N.V. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Keygene N.V.

Q: What technology areas does Keygene N.V. focus on?

Keygene N.V.'s top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 46 patents. Grants appear in 18 CPC subclasses total.

USPTO PatentsView assignee record - 78 granted patents across 18 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Keygene ranks #4,522 of 49,997 tracked US assignees by granted-patent volume, with 78 patents across 18 technology areas.

#4,522
of 49,997 US assignees by volume: Top 27%
by Innovation Score (43.8/100): 15.1
avg claims per patent: -52%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4522 · Foreign Corporation #4,522 · 78 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 78 grants
TOP-DECILE #4,522/49,997
PHOTO-FINISH Heptares Therapeutics
CPC-FOCUS C12N · 18 areas
INNOV-PAR 43.8/100
CLAIMS-RICH 15.1 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -52% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Heptares Therapeutics Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Real Value · near

44
Beijing BOE Chatani · near

44
C&D Zodiac · near

44
Keygene · this assignee

44
Suse · near

44
3D Lighting… · lowest

7

What this shows Keygene's Innovation Score is 43.8/100 (top 27% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Keygene's grants concentrate

Keygene N.V. is a focused PatentsView assignee: 18 CPC subclasses with 59% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2016 (14 grants) versus a trough of 3 in 2020. By volume, Keygene sits between Heptares Therapeutics Limited and NEC Energy Devices, Ltd..

Keygene's three-year grant acceleration

Keygene N.V. shows 12 grants in 2022–2024 against only 17 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Heptares Therapeu…

78
Indian Institute…

78
Interrad Medical

78
KAO Germany

78
Leonhard Kurz Sti…

78
Marmon Foodservice

78
Maytronics

78
NEC Energy Devices

78
Keygene ◀

78

What this shows Keygene holds 78 patents at rank #4,522, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Keygene

By rank, the assignees closest to #4,522 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Keygene's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Keygene, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (44 here).

C&D Zodiac, Inc. 44 Beijing BOE Chatani Electronics Co., Ltd. 44 Suse LLC 44 Real Value LLC 44

Similar claim depth

Nearest assignees by average claims per patent (15.1 here).

STI Holdings, Inc. 15.1 avg Theravance Biopharma R&D IP, LLC 15.1 avg Rolls-royce plc 15.1 avg Flint Hills Scientific, L.L.C. 15.1 avg

Keygene's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 27% higher than 73% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Keygene N.V. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	7	9.0%
2016	14	17.9%
2017	12	15.4%
2018	9	11.5%
2019	6	7.7%
2020	3	3.8%
2021	8	10.3%
2022	6	7.7%
2023	3	3.8%
2024	3	3.8%
2025partial year	7	9.0%

Which technologies does Keygene N.V. patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 46

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 41

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 20

A01H - NEW Plants OR ; NON-TRANSGENIC; Processes FOR Obtaining THEM; Plant Reproduction BY Tissue Culture Techniques 14

C07K - Peptides 13

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 11

Y02A - Technologies FOR Adaptation TO Climate Change 10

C12Y - Enzymes 6

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 5

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 2

G06T - Image Data Processing OR Generation, IN General 1

G06V - Image OR Video Recognition OR Understanding 1

G02B - Optical Elements, Systems OR Apparatus 1

B07C - Postal SORTING; Sorting Individual Articles, OR Bulk Material FIT TO BE Sorted Piece-meal, e.g. BY Picking 1

Top 15 of 18 technology areas

Where it ranks

Overall rank by patents

#4,522

of 49,997 tracked assignees

Innovation Score

43.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Keygene N.V.'s patent record in context - here's where to go next.

Keygene N.V.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 59% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #4,522 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Keygene N.V. against Heptares Therapeutics Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.